Agentix Corp (AGTX)
Agentix Corp is a clinical-stage biotechnology company listed on OTC Markets under the ticker AGTX. The company is developing therapies aimed at metabolic diseases in the United States, with two lead programs: AGTX-2004, a peripherally acting CB1 receptor antagonist, and AGTX-2003, a peripherally acting CB1 receptor inverse agonist. Both candidates have shown activity in animal studies, including models relevant to obesity, type 2 diabetes, and non-alcoholic fatty liver disease. The company adopted the Agentix name in June 2019 after operating as FairWind Energy, Inc. Agentix Corp was founded in 2020 and is based in Dana Point, California.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-AGTX
|
$0.016
|
-19.0% Downside
|
Overvalued
|
Not available
|
Not available
|
Fair
|
0.0%
|
November 20, 2026
|
801.339 K
|
1.181 M
|
32.1%
|
-409,328.2
|
4.0%
|
